An observational study in Obesity, Diabetes and Metabolic Diseases, sponsored by University of Lorraine. Recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-10-27.
Sponsored by University of Lorraine · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 476 studies in Obesity with a site in France — 112 open to participants now, 128 under way, 25 of them phase 3. Obesity · France.
Among the 476 studies in Obesity with a site in France, this one has the largest planned enrollment of the 121 observational ones that give a count, is one of 23 that started in 2016, is one of 121 observational ones, reaches primary completion later than 22 of the 127 other live ones, and was the 168th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →112 of the 476 studies in Obesity with a site in France are open now. Recruiting first, the newest first:
Nantes University Hospital · Sites in France
Ages 18+
Laboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques et Pathologiques · Sites in France
Ages 50–75
AstraZeneca · Sites in France, United States, Argentina and 13 more countries
Ages 18+
Novo Nordisk A/S · Sites in France, United States, Belgium and 7 more countries
Ages 18+
Hospices Civils de Lyon · Sites in France
Ages 18–75
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
476 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 21 · Phase 3 61 · Phase 4 14
First in 2001; this study’s year is marked. 23 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20,000 is above the median of 115 across 2,159 observational studies indexed under Obesity.
Median enrollment 80 across the 355 interventional studies, 133 across the 121 observational. Of the 295 that completed or were terminated, 16 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 476 have an industry lead sponsor. The 10 most frequent:
University of Lorraine is the lead sponsor of 12 studies on the registry; 4 are open to participants now.
University of Lorraine has 1 study filed under Obesity — fewer than ten, so there is no comparison to draw.
31 of the studies in Obesity with a site in France that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT03516968Phase 3Hospices Civils de LyonMonthly Boluses Versus Daily Doses for Correcting Blood Vitamin D Deficit in Obese Children and Adolescents | 2027-03 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07225686Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-08-20 |
Add all 31 to your calendar (.ics) → With an account.
Among the 476 studies in Obesity with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the role of vitamin status and epigenetic mechanisms on severe obesity related-complications.
Patients who undergo bariatric surgery following french national guidelines (HAS 2009)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Evaluation of folate mediated one-carbon metabolic pathway parameters (Folates, Vitamin B12, Methionine, Homocysteine) on severe obesity-related complications before and after bariatric surgery
Time frame: 10 years
Evaluation of DNA Methylation on severe obesity-related complications before and after bariatric surgery
Time frame: 10 years
The record gives a start of Jan 2016, a primary completion of Jan 2026 and a completion of Jan 2026. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Lorraine